![]() ![]() Animal models show curative effects for AA with general or topical JAK inhibitors. JAK inhibitors have been shown to be efficacious in inflammatory skin conditions like psoriasis and dermatitis, and they are being investigated in inflammatory bowel disease. 5 Other treatments on the horizon for AA include Janus kinase (JAK) inhibitors and systemic immunomodulators. ![]() A recent study by Avitabile et al showed decreased Th17 and IL-17 infiltrates in the skin of AA patients after successful contact immunotherapy with squaric acid dibutylester. 3, 4Ĭurrent treatments for AA include topical and intralesional steroids for less severe cases and contact immunotherapy for extensive hair loss. 1 Specifically, T-helper 17 (Th17) cells and interleukin-17 (IL-17) have been implicated in the development of AA. It is thought to be a T-cell-mediated autoimmune disease that attacks the hair follicle, and both the innate and adaptive immune systems have been implicated in the pathogenesis. 1 Onset typically occurs in younger patients, with 66% presenting before age 30 and only 20% presenting after age 40. Though still poorly understood, FMT is emerging as an effective therapy for recurrent CDI, and it is being investigated as a treatment option for other inflammatory conditions.ĪA is one of the most common autoimmune disorders, affecting about 4.5 million people in the United States. This suggests not only an intestinal effect but a profound immunological response to FMT. This report highlights 2 patients with coexisting AA and recurrent CDI who experienced hair regrowth after FMT. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |